Log In
Print
BCIQ
Print
Print this Print this
 

Intranasal sumatriptan powder, OptiNose sumatriptan (AVP-825)

  Manage Alerts
Collapse Summary General Information
Company OptiNose Inc.
DescriptionLow-dose sumatriptan powder delivered intranasally using OptiNose Bi-Directional Breath Powered intranasal delivery technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat migraine with or without aura; Treat moderate to severe acute migraine pain
Regulatory Designation U.S. - Standard Review (Treat acute migraine)
Partner Otsuka Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$110.0M

$20.0M

$90.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today